Pfizer tests COVID pills as a preventative drug


September 27, 2021

In the Associated Press

New York-Pipizer began testing COVID-19, a potential antiretroviral drug, in close contact with the virus.

The article continues below …

The drug maker announced on Monday that it was studying the pill, which is being developed with low doses of the drug Ritanovir, in people living at least 18 years of age and living with an infected person.

Pfizer plans to enroll 2,660 people in the final phase of the study. Participants received a combination medication or counterfeit medication twice a day for five to 10 days.

Researchers hope that the use of Ritanovir will help reduce the risk of complications, so it will remain active for a long time.

“If successful, we believe this therapy will help stop the virus early,” said Dr. Michael Dolston, chief psychologist at Pfizer.

Pfizer Inc. is also studying treatment for people infected with the virus. It is intended to treat patients at the first sign of illness without the need for hospitalization. The pharmacist expects to see the results of these studies later in the year.

The pill is designed to block the key enzyme needed to replicate the virus.


More on panel:

-The United States has enough COVID-19 vaccines for vaccines, childhood vaccines

– At the end of the Covenant, Rhode festivities took place in Norway

– Descriptive – Who is eligible for Pfizer promotion photos in the US?

Report correction or typing.

Copyright 2021 Associated Press. all rights reserved. This article may not be published, distributed, rewritten, or redistributed.

Leave a Comment